Abstract
According to some authors, infection caused by M. pneumoniae is one of the most common in the current epidemic season of 2020–2021 worldwide. This fact is particularly important now because of the need for differential diagnosis between mild COVID-19 and respiratory infection caused by M. pneumoniae, as well as for timely administration of causal therapy. Materials and methods. In this study, we analyzed the frequency of pneumonia caused by M. pneumoniae detected among children admitted to the Pediatric Department for Infectious Diseases of Khimki Hospital over the last 5 years. Results. We observed an increase in the proportion of patients hospitalized with community-acquired pneumonia, primarily between October 2017 and April 2018, as well as in the spring of 2020. In 31% to 67% of children treated in 2020–2021 (depending on the month and season), community-acquired pneumonia was caused by M. pneumoniae. We also analyzed clinical characteristics of community-acquired pneumonia caused by M. pneumoniae and other pathogens. In addition to that, we report a case of mixed infection (M. pneumoniae plus Epstein-Barr virus) and provide a rationale for administration of meglumine acridone acetate (Cycloferon) as a part of comprehensive treatment for this pathology. Key words: community-acquired pneumonia, children, infection caused by Mycoplasma pneumoniae, meglumine acridone acetate
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
